发明名称 |
USE OF A CD40:CD154 BINDING INTERRUPTOR TO TREAT IMMUNOLOGICAL COMPLICATIONS OF THE EYE |
摘要 |
The invention relates generally to the treatment and inhibition of immunological complications of the eye. Such complications include unwanted immune responses resulting in an ocular inflammatory disease, resulting from a corneal or retinal graft transplantation or resulting from ocular angiogenesis, particularly ocular neovascularization. The invention relates in particular to the inhibition, treatment, or reversal of immune-system driven rejection of grafted corneal or retinal tissue or cells in a recipient host and to the treatment or inhibition of ocular inflammatory disease or ocular neovascularization in a host. Compositions and methods disclosed herein capitalize on the discovery that immunological complications of the eye can be inhibited using a CD40:CD154 binding interruptor, either alone or in combination with another immunomodulator or immunosuppressor. An exemplary CD40:CD154 binding interruptor is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody.
|
申请公布号 |
CA2387889(A1) |
申请公布日期 |
2001.05.03 |
申请号 |
CA20002387889 |
申请日期 |
2000.10.19 |
申请人 |
BIOGEN, INC.;SCHEPENS EYE RESEARCH INSTITUTE |
发明人 |
LOBB, ROY;VAISHNAW, AKSHAY K.;DANA, M. REZA;BURKLY, LINDA C.;ADELMAN, BURT |
分类号 |
A61K9/06;A61F2/14;A61K9/08;A61K39/395;A61K45/00;A61L27/00;A61P27/02;A61P29/00;C07K16/28;(IPC1-7):A61K39/395;A61K31/00;A61K38/13 |
主分类号 |
A61K9/06 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|